Ardelyx Inc's stock surged by 19.90% today, reaching a 52-week high amid mixed market conditions, with the Nasdaq-100 down 0.61% and the S&P 500 up 0.01%.
This increase is attributed to Ardelyx's announcement of a remarkable $274 million revenue for IBSRELA in 2025, marking a 73% growth from the previous year. The company also provided an optimistic outlook for 2026, expecting revenue to reach between $410 million and $430 million, reflecting strong market demand and acceptance in the irritable bowel syndrome treatment sector. Additionally, Ardelyx has initiated a Phase 3 clinical trial for IBSRELA, which is expected to bolster its growth prospects further.
The strong performance of IBSRELA, coupled with the company's strategic advancements in research and development, positions Ardelyx favorably in the market, suggesting a robust future trajectory despite the mixed performance of broader market indices.
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 14.33 USD with a low forecast of 10.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 14.33 USD with a low forecast of 10.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.850
Low
10.00
Averages
14.33
High
19.00
Current: 7.850
Low
10.00
Averages
14.33
High
19.00
TD Cowen
Buy
upgrade
$10 -> $13
2026-01-29
New
Reason
TD Cowen
Price Target
$10 -> $13
AI Analysis
2026-01-29
New
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ardelyx to $13 from $10 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Jefferies
Buy
upgrade
$8 -> $15
2026-01-27
New
Reason
Jefferies
Price Target
$8 -> $15
2026-01-27
New
upgrade
Buy
Reason
Jefferies raised the firm's price target on Ardelyx to $15 from $8 and keeps a Buy rating on the shares. The firm, which views Ardelyx as "among the most underrated and under-the-radar biotech launches," sees continued Ibsrela execution in 2026, but also a significantly bigger tail driven by IBS-C, new CIC, and potentially longer run on its intellectual property. The firm estimates $1.5B-$2B in peak sales in 2035, up from a prior call of $1B in 2032, but sees further upside if the new 2041 formulation patent is defendable, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARDX
Unlock Now
Citi
Buy
maintain
$11 -> $14
2026-01-09
Reason
Citi
Price Target
$11 -> $14
2026-01-09
maintain
Buy
Reason
Citi raised the firm's price target on Ardelyx to $14 from $11 and keeps a Buy rating on the shares. The company's outlook for $1B in annual Ibsrela revenue by 2029 is faster acceleration than Citi previously modeled, the analyst tells investors in a research note.
BTIG
Julian Harrison
Buy
maintain
$14 -> $17
2026-01-09
Reason
BTIG
Julian Harrison
Price Target
$14 -> $17
2026-01-09
maintain
Buy
Reason
BTIG analyst Julian Harrison raised the firm's price target on Ardelyx to $17 from $14 and keeps a Buy rating on the shares. Ardelyx pre-announced strong FY25 results and issued 2026 Ibsrela guidance of $410-$430M, supporting confidence in a path to more than $1B peak sales, aided by a large, underpenetrated IBS-C market, a new Phase 3 CIC trial, and extended IP potential to 2041, the analyst tells investors in a research note. Alongside growing Xphozah revenue, a progressing pipeline, and a strong cash position, Ardelyx is well-positioned to sustain commercial growth and fund future development, the firm says.
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
